Dr. Weihua Li

ForLong Bio recently announced that Dr. Li Weihua officially joined the company as CMO (Chief Medical Officer) on January 15, 2022. Dr. Li received his Ph.D. in Internal Medicine (Infectious Diseases) from West China Medical Center of Sichuan University (formerly West China Medical University), and has been engaged in post-doctoral research on the pathogenesis of HBV-associated hepatocellular carcinoma at Naval Medical University (formerly Second Military Medical University) and Baylor College of Medicine in the United States for many years. He has been engaged in medical treatment, teaching and scientific research for more than 20 years in domestic large Class III teaching hospitals, and has solid professional knowledge and rich clinical experience in the fields of digestive tract tumors, autoimmunity and HBV-related liver diseases. He has served as a professor of gastroenterology, hosted a number of National Natural Science Foundation projects, provincial and ministerial level and international cooperation projects, and served as a Standing Committee member of a number of liver disease-related professional committees, including liver cancer, cirrhosis and fatty liver disease, and won the "Pearl River Contribution Award". in recent years, he has successively served as the medical team leader and CMO in well-known domestic pharmaceutical companies such as Hansen Pharmaceutical, Qilu Pharmaceutical and Biotech companies, leading or participating in the clinical development of more than 20 new drugs, including the clinical development strategy, program design and implementation of "first in class or best in class" drugs. He has rich experience in the research and development of new drugs in many fields such as cancer, hepatitis B, diabetes, renal anemia and rare diseases.

The company is a preclinical Biotech company with a leading long-acting technology platform, Fc engineering technology platform, biomolecular artificial evolution technology platform and synthetic novel cytokine platform. Has completed tens of millions of yuan angel round financing in 2021.
Dr. Yu Xiaoxu, CEO of Furong Bio, said, "Furong is very pleased to welcome Dr. Li to join and assume the role of Chief Medical Officer. As a clinical expert engaged in clinical medical teaching and research for more than 20 years and a senior expert in clinical research and development of new drugs, Dr. Li has deep attains in new drug development strategy and clinical trial design, and has rich experience in clinical development and operation and drug transformation. Her addition will help accelerate the development of innovative pharmaceutical pipeline products to market and the sustainability of pipeline development."